Enhertu 100 mg Injection: Revolutionary HER2-Directed Antibody-Drug Conjugate (ADC)
Are you looking for a trusted Enhertu 100 mg injection exporter from India? Ernest Oncology, a specialized vertical of Ernest Pharmaceutical Pvt. Ltd., is a premier global bulk supplier and distributor of cutting-edge oncology biologics. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that next-generation cancer therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.
Detailed Product Overview: What is Enhertu 100 mg?
Enhertu 100 mg (Fam-trastuzumab deruxtecan-nxki) is a breakthrough antibody-drug conjugate (ADC) designed for targeted cancer therapy. It represents a paradigm shift in precision medicine, combining the targeting power of a monoclonal antibody with the cell-killing potency of a topoisomerase I inhibitor.
Manufactured by AstraZeneca and Daiichi Sankyo, Enhertu is precision-engineered to treat cancers with varying levels of HER2 expression. For international B2B procurement, Enhertu 100 mg offers a world-class solution for patients who have progressed on prior anti-HER2 regimens.
Primary Therapeutic Indications
Enhertu 100 mg injection is clinically indicated for the management of
HER2-Positive Breast Cancer: For patients with unresectable or metastatic breast cancer who have received a prior anti-HER2-based regimen.
HER2-Low Breast Cancer: A groundbreaking indication for patients with metastatic breast cancer previously treated with chemotherapy.
HER2-Positive Gastric Cancer: Treatment of locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
HER2-Mutant NSCLC: Targeted therapy for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC).
Mechanism of Action: How Enhertu Works
Enhertu utilizes a unique "payload" technology to destroy cancer cells from within:
Targeted Binding: The antibody component (trastuzumab) binds specifically to HER2 receptors on the surface of cancer cells.
Internalization: Once bound, the cancer cell absorbs the Enhertu molecule.
Payload Release: Inside the cell, the linker is cleaved, releasing the potent chemotherapy payload (deruxtecan).
Bystander Effect: Unlike older ADCs, Enhertu features a "bystander effect," where the payload can cross into neighboring cancer cells, even if they have lower HER2 levels.
Administration and Safety Guidelines
Standard Dosage: Administered as an intravenous (IV) infusion by a qualified oncology professional. The typical dose is 5.4 mg/kg or 6.4 mg/kg every three weeks, depending on the indication.
Storage: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake.
Key Precautions:
Interstitial Lung Disease (ILD): Monitor for cough, dyspnea, or fever; ILD/pneumonitis can be severe or fatal.
Neutropenia: Regular complete blood counts (CBC) are mandatory to monitor for low white blood cell counts.
Left Ventricular Dysfunction: Monitor cardiac function (LVEF) before and during treatment.
Fetal Toxicity: Not for use during pregnancy; effective contraception is required.
Why Choose Ernest Oncology?
Authentic Indian Exporter: Direct access to genuine international oncology brands, ensuring 100% authenticity and competitive bulk pricing.
Cold-Chain Excellence: Validated temperature-controlled packaging and logistics to maintain the biochemical stability of sensitive biologics.
Global Distribution Mastery: Expertise in navigating the specialized regulatory and customs landscapes of the USA, UK, Australia, and South Africa.
Bulk Supply Continuity: We specialize in fulfilling large-scale orders for specialty clinics, government hospitals, and regional distributors.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
